Continental Advisors’s iShares Biotechnology ETF IBB Stock Holding History

Continental Advisors’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-5,400	Closed	-$731K	–	80
2020 Q3	$731K	Hold	5,400	–	–	0.39%	68
2020 Q2	$738K	Hold	5,400	–	–	0.39%	65
2020 Q1	$582K	Hold	5,400	–	–	0.43%	64
2019 Q4	$651K	Hold	5,400	–	–	0.31%	67
2019 Q3	$537K	Hold	5,400	–	–	0.32%	65
2019 Q2	$589K	Buy	+5,400	New	+$574K	0.33%	64
2015 Q1	–	Sell	-28,800	Closed	-$3.18M	–	156
2014 Q4	$2.91M	Buy	+28,800	New	+$2.8M	0.59%	56
2013 Q3	–	Sell	-41,850	Closed	-$2.74M	–	137
2013 Q2	$2.43M	Buy	+41,850	New	+$2.42M	0.68%	45

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Continental Advisors's IBB Position: Q4 2020 in Review

Continental Advisors sold out of iShares Biotechnology ETF (IBB) in Q4 2020, closing a stake of 5,400 shares — an estimated $731K sold.

Continental Advisors first reported a position in IBB in Q2 2013 and held it in 8 quarters. The position peaked at $2.91M in Q4 2014. 856 funds tracked by Wall St. Rank hold IBB as of Q4 2020.

Continental Advisors reported no remaining iShares Biotechnology ETF position as of Q4 2020 after selling out during the quarter.
Continental Advisors sold 5,400 iShares Biotechnology ETF shares in Q4 2020, an estimated $731K.
Continental Advisors first reported a position in iShares Biotechnology ETF in Q2 2013 and held it in 8 quarters.
Continental Advisors's iShares Biotechnology ETF position peaked at $2.91M in Q4 2014.
856 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q4 2020.

Based on Continental Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.